Does the media favor TLRY or NMRA?

In the previous week, Tilray Brands had 17 more articles in the media than Neumora Therapeutics. MarketBeat recorded 19 mentions for Tilray Brands and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat Tilray Brands' score of 0.18 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 3 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EOLS or NMRA more profitable?

Neumora Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -10.85%. Evolus' return on equity of 0.00% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evolus -10.85% N/A -13.00% Neumora Therapeutics N/A -242.28% -131.32%

Does the media favor EOLS or NMRA?

In the previous week, Evolus and Evolus both had 2 articles in the media. Neumora Therapeutics' average media sentiment score of 0.67 beat Evolus' score of 0.51 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CTNM or NMRA more profitable?

Contineum Therapeutics' return on equity of -24.73% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -24.73% -23.51% Neumora Therapeutics N/A -242.28% -131.32%

Does the media favor CTNM or NMRA?

In the previous week, Contineum Therapeutics had 5 more articles in the media than Neumora Therapeutics. MarketBeat recorded 7 mentions for Contineum Therapeutics and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat Contineum Therapeutics' score of -0.14 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASMB or NMRA?

In the previous week, Neumora Therapeutics had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 2 mentions for Neumora Therapeutics and 1 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 1.04 beat Neumora Therapeutics' score of 0.67 indicating that Assembly Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neumora Therapeutics (NMRA) Competitors

$0.73 -0.05 (-6.06%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.74 +0.01 (+1.87%)

As of 04:56 AM Eastern

Compare

NMRA vs. TLRY, OVID, EOLS, CTNM, and ASMB

Should you buy Neumora Therapeutics stock or one of its competitors? Neumora Therapeutics's main competitors and comparable companies include Tilray Brands (TLRY), Ovid Therapeutics (OVID), Evolus (EOLS), Contineum Therapeutics (CTNM), and Assembly Biosciences (ASMB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Neumora Therapeutics compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Neumora Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -13.11%. Tilray Brands' return on equity of -7.76% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-13.11%	-7.76%	-5.59%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Tilray Brands has higher revenue and earnings than Neumora Therapeutics. Tilray Brands is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$915.45M	0.61	-$121.40M	-$1.08	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Tilray Brands has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market.

Tilray Brands presently has a consensus target price of $7.00, suggesting a potential upside of 70.32%. Neumora Therapeutics has a consensus target price of $6.57, suggesting a potential upside of 798.60%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Tilray Brands had 17 more articles in the media than Neumora Therapeutics. MarketBeat recorded 19 mentions for Tilray Brands and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat Tilray Brands' score of 0.18 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Neumora Therapeutics beats Tilray Brands on 9 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Neumora Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -23.64% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-23.64%	-20.52%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Ovid Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.71, suggesting that its stock price is 171% more volatile than the broader market.

Ovid Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 133.46%. Neumora Therapeutics has a consensus price target of $6.57, indicating a potential upside of 798.60%. Given Neumora Therapeutics' higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Ovid Therapeutics has higher revenue and earnings than Neumora Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	69.23	-$17.41M	-$0.31	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

In the previous week, Neumora Therapeutics had 2 more articles in the media than Ovid Therapeutics. MarketBeat recorded 2 mentions for Neumora Therapeutics and 0 mentions for Ovid Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat Ovid Therapeutics' score of 0.34 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
Neumora Therapeutics	Positive

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ovid Therapeutics beats Neumora Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to Evolus?

Evolus (NASDAQ:EOLS) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Evolus has higher revenue and earnings than Neumora Therapeutics. Evolus is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.78	-$51.64M	-$0.52	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Evolus has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.71, suggesting that its share price is 171% more volatile than the broader market.

In the previous week, Evolus and Evolus both had 2 articles in the media. Neumora Therapeutics' average media sentiment score of 0.67 beat Evolus' score of 0.51 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evolus presently has a consensus target price of $14.50, indicating a potential upside of 81.25%. Neumora Therapeutics has a consensus target price of $6.57, indicating a potential upside of 798.60%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

90.7% of Evolus shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 5.0% of Evolus shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Neumora Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -10.85%. Evolus' return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-10.85%	N/A	-13.00%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Summary

Neumora Therapeutics beats Evolus on 9 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Contineum Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market.

47.7% of Neumora Therapeutics shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Contineum Therapeutics' return on equity of -24.73% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Contineum Therapeutics has higher revenue and earnings than Neumora Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	9.41	-$59.98M	-$1.73	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Contineum Therapeutics presently has a consensus target price of $20.80, indicating a potential upside of 66.27%. Neumora Therapeutics has a consensus target price of $6.57, indicating a potential upside of 798.60%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Contineum Therapeutics had 5 more articles in the media than Neumora Therapeutics. MarketBeat recorded 7 mentions for Contineum Therapeutics and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat Contineum Therapeutics' score of -0.14 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neumora Therapeutics beats Contineum Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Assembly Biosciences has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market.

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Assembly Biosciences currently has a consensus price target of $47.50, indicating a potential upside of 98.16%. Neumora Therapeutics has a consensus price target of $6.57, indicating a potential upside of 798.60%. Given Neumora Therapeutics' higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Neumora Therapeutics has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. Assembly Biosciences' return on equity of -0.02% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Assembly Biosciences has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.75	-$6.12M	$1.02	23.50
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

In the previous week, Neumora Therapeutics had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 2 mentions for Neumora Therapeutics and 1 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 1.04 beat Neumora Therapeutics' score of 0.67 indicating that Assembly Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Assembly Biosciences beats Neumora Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Neumora Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMRA vs. The Competition

Export

Metric	Neumora Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$146.28M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-0.59	792.28	274.09	25.69
Price / Sales	N/A	861.37	642.55	79.71
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	1.18	10.58	10.47	6.32
Net Income	-$236.93M	$2.81B	$3.49B	$359.73M
7 Day Performance	-2.49%	-0.12%	-0.68%	0.17%
1 Month Performance	-52.05%	-1.34%	-3.18%	-3.27%
1 Year Performance	-60.04%	2.86%	15.12%	5.58%

Neumora Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMRA Neumora Therapeutics	2.4487 of 5 stars	$0.73 -6.1%	$6.57 +798.6%	-61.7%	$146.28M	N/A	N/A	63	News Coverage
TLRY Tilray Brands	3.9622 of 5 stars	$4.08 +2.3%	$7.00 +71.6%	-66.9%	$543.45M	$915.45M	N/A	3,595	Analyst Forecast
OVID Ovid Therapeutics	2.4217 of 5 stars	$2.71 +0.7%	$6.00 +121.4%	+104.0%	$525.35M	$7.25M	N/A	23
EOLS Evolus	2.7093 of 5 stars	$7.99 +1.7%	$14.50 +81.5%	+29.2%	$519.16M	$297.18M	N/A	353	Positive News
CTNM Contineum Therapeutics	1.8001 of 5 stars	$13.55 +0.1%	$20.80 +53.5%	+13.1%	$509.01M	$50M	N/A	51

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMRA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neumora Therapeutics (NMRA) Competitors

NMRA vs. TLRY, OVID, EOLS, CTNM, and ASMB

How does Neumora Therapeutics compare to Tilray Brands?

Summary

How does Neumora Therapeutics compare to Ovid Therapeutics?

Summary

How does Neumora Therapeutics compare to Evolus?

Summary

How does Neumora Therapeutics compare to Contineum Therapeutics?

Summary

How does Neumora Therapeutics compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neumora Therapeutics (NMRA) Competitors

NMRA vs. TLRY, OVID, EOLS, CTNM, and ASMB

How does Neumora Therapeutics compare to Tilray Brands?

Is TLRY or NMRA more profitable?

Which has stronger earnings & valuation, TLRY or NMRA?

Which has more volatility and risk, TLRY or NMRA?

Do analysts rate TLRY or NMRA?

Does the media favor TLRY or NMRA?

Do institutionals & insiders have more ownership in TLRY or NMRA?

Summary

How does Neumora Therapeutics compare to Ovid Therapeutics?

Is OVID or NMRA more profitable?

Which has more volatility and risk, OVID or NMRA?

Do analysts prefer OVID or NMRA?

Which has stronger valuation and earnings, OVID or NMRA?

Does the media favor OVID or NMRA?

Do institutionals and insiders have more ownership in OVID or NMRA?

Summary

How does Neumora Therapeutics compare to Evolus?

Which has better earnings & valuation, EOLS or NMRA?

Which has more risk & volatility, EOLS or NMRA?

Does the media favor EOLS or NMRA?

Do analysts prefer EOLS or NMRA?

Do institutionals & insiders have more ownership in EOLS or NMRA?

Is EOLS or NMRA more profitable?

Summary

How does Neumora Therapeutics compare to Contineum Therapeutics?

Which has more risk & volatility, CTNM or NMRA?

Do insiders & institutionals believe in CTNM or NMRA?

Is CTNM or NMRA more profitable?

Which has higher valuation and earnings, CTNM or NMRA?

Do analysts recommend CTNM or NMRA?

Does the media favor CTNM or NMRA?

Summary

How does Neumora Therapeutics compare to Assembly Biosciences?

Which has more volatility & risk, ASMB or NMRA?

Do insiders and institutionals believe in ASMB or NMRA?

Do analysts recommend ASMB or NMRA?

Is ASMB or NMRA more profitable?

Which has preferable earnings & valuation, ASMB or NMRA?

Does the media favor ASMB or NMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools